A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Trial Profile

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Benegrastim (Primary) ; Pegfilgrastim
  • Indications Neutropenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Generon (Shanghai) Corporation
  • Most Recent Events

    • 06 Jan 2015 New trial record
    • 08 Dec 2014 Primary endpoint has been met (The efficacy of various single cycle doses of F-627 to measure the duration of moderate neutropenia post Chemotherapy administration as compared with the standard dosing of Neulasta) according to a Generon media release.
    • 08 Dec 2014 Status changed from recruiting to completed according to a Generon (Shanghai) Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top